Parpi For Somatic Brca1/2 And Other Dna Repair Gene Mutations In Women With Metastatic Breast Cancer

PARPi for somatic BRCA1/2 and other DNA repair gene mutations in women with metastatic breast cancer

A study of talazoparib in somatic BRCA1/2 mutant MBC identified by cfDNA or tumor tissue genotyping

How Genetic Mutations Affect Metastatic Breast Cancer Disease Progression and Prognosis

Patient Empowerment Network

Testing for BRCA Germline Mutations in the Clinic and the Mechanism of Action of PARP Inhibitors

What is a PARP Inhibitor? | Dana-Farber Cancer Institute | Science Illustrated

Dana-Farber Cancer Institute

PARP Inhibitors for BRCA-Mutated TNBC

Detecting Somatic BRCA1/2 Mutations in Ovarian Cancer

PARP Inhibitors in 2020: Where Are We Now, and Where Are We Going | Webinar | Ambry Genetics

The role of BRCA and PARP in DNA repair and BRCA-related breast cancer

EMJ

ACT Genomics Dinner Symposium | Moving from BRCA1/2 to HRD: Beyond Woman’s Cancers

Gene Expression Algorithm for Prioritizing Treatment Options in BRCA1/2 Carriers with Breast Cancer

Inherited Cancer Registry (ICARE)

PARP Inhibitors for BRCA-Associated TNBC

Dr. Litton on Activity of Talazoparib in Advanced BRCA1/2+ Breast Cancer

Emerging Options for BRCA-Mutated Breast Cancer Treatment

Germline and Somatic DNA Repair Defects in Prostate Cancer

Grand Rounds in Urology

Treating patients with breast cancer and a BRCA 1/2 mutation: 2022 ESMO Florida

Total Health | Oncology

Treating BRCA breast cancer with PARP inhibition

TBCRC 048: olaparib monotherapy in metastatic breast cancer

DNA Repair: PARP, A Target in Evolution

BRCA across tumour types

European Society for Medical Oncology (ESMO)